Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR regimen in newly diagnosed CLL/SLL
NCT06547944Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Maximum Tolerated Dose at 4 months and Adverse Events. Started Jan 2024; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06547944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547944.